Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Tuesday, remained unchanged from the previous trading day ,before settling in for the closing price of $2.02. Within the past 52 weeks, XERS’s price has moved between $1.46 and $3.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 195.35%. The company achieved an average annual earnings per share of 23.17%. With a float of $125.32 million, this company’s outstanding shares have now reached $138.13 million.
Let’s determine the extent of company efficiency that accounts for 377 employees.
Xeris Biopharma Holdings Inc (XERS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 10.77%, while institutional ownership is 41.15%. The most recent insider transaction that took place on Mar 14 ’24, was worth 9,720. In this transaction Director of this company bought 4,500 shares at a rate of $2.16, taking the stock ownership to the 11,000 shares. Before that another transaction happened on Nov 27 ’23, when Company’s Director bought 5,400 for $1.87, making the entire transaction worth $10,098. This insider now owns 5,400 shares in total.
Xeris Biopharma Holdings Inc (XERS) Recent Fiscal highlights
As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.1 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.1) by $0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.17% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.23 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Looking closely at Xeris Biopharma Holdings Inc (NASDAQ: XERS), its last 5-days average volume was 1.13 million, which is a drop from its year-to-date volume of 2.25 million. As of the previous 9 days, the stock’s Stochastic %D was 11.66%. Additionally, its Average True Range was 0.13.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 31.11%, which indicates a significant increase from 10.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.90% in the past 14 days, which was lower than the 77.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.54, while its 200-day Moving Average is $2.24. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $2.05. Second resistance stands at $2.09. The third major resistance level sits at $2.11. If the price goes on to break the first support level at $2.00, it is likely to go to the next support level at $1.98. Now, if the price goes above the second support level, the third support stands at $1.94.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 283.71 million based on 140,453K outstanding shares. Right now, sales total 163,910 K and income totals -62,260 K. The company made 44,390 K in profit during its latest quarter, and -13,390 K in sales during its previous quarter.
